You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Medications Articles
Popular Medications Articles
Highly Recommended Medications Articles
Send a link to this page to your friends and colleagues.
On April 20, 2006, Eli Lilly & Co. told Diabetes Health that the U.S. Food and Drug Administration has granted priority review status for Arxxant, its potential “first-in-class treatment” for diabetic retinopathy.
Diabetic retinopathy is a result of damage to the small blood vessels in the back of the eye caused by diabetes. According to Eli Lilly, about 40 to 45 percent of Americans diagnosed with diabetes have some stage of diabetic retinopathy, which can lead to vision loss and blindness.
“Currently, there are no approved prescription products to treat diabetic retinopathy, says Eli Lilly. “Arxxant has the potential to represent a significant improvement in the treatment of diabetic retinopathy.”
Jul 1, 2006
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.